Understanding ADHD and addiction in patients
Addictions and Attention Deficit Disorder With or Without Hyperactivity
This study is trying to learn more about how ADHD and addiction happen together in people by collecting information from patients over a year to see how well treatments work.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 3 sites (Nantes, Loire-Atlantique and 2 other locations) |
| Trial ID | NCT06232226 on ClinicalTrials.gov |
What this trial studies
This study focuses on collecting detailed sociodemographic, clinical, and neuropsychological data from patients diagnosed with both Attention Deficit Hyperactivity Disorder (ADHD) and addiction. Participants will undergo two visits: one for initial evaluation and another after 12 months. Each visit will include structured clinical interviews and neuropsychological assessments conducted by trained professionals. The aim is to enhance understanding of the co-occurrence of these conditions and the effectiveness of treatment approaches.
Who should consider this trial
Good fit: Ideal candidates are individuals aged over 15 years with a recent diagnosis of ADHD and confirmed addictive disorders who have not yet started treatment with methylphenidate.
Not a fit: Patients with higher cognitive disorders or those unable to participate in the required visits will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients dealing with both ADHD and addiction.
How similar studies have performed: While studies on ADHD and addiction exist, this specific approach of systematic data collection in a cohort is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * Patients aged over 18 years * For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago * For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed * Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019) * For patients who can actually benefit from MPH: who have not yet started taking MPH * Social security affiliates Exclusion Criteria : * Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible * Presenting difficulties in reading or writing the French language making data collection impossible * Unable to commit to being available for the 2 visits planned as part of the cohort * Under guardianship or legal protection * Patients who have used psychoactive substances within 12 hours prior to their visit
Where this trial is running
Nantes, Loire-Atlantique and 2 other locations
- Nantes University Hospital — Nantes, Loire-Atlantique, France (Recruiting)
- CHRU de Brest — Brest, France (Recruiting)
- CHRU de Tours — Tours, France (Recruiting)
Study contacts
- Study coordinator: Clémence CABELGUEN, PH
- Email: clemence.cabelguen@chu-nantes.fr
- Phone: 33 2 40 84 61 16
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.